The two studies used Drop-seq RNA profiling to discover essentially all cell types and establish cell lineages in a model organism flatworm.
The company said PerkinElmer will pay A$.28 per share for its 89.9 million outstanding shares, a 100 percent premium to RHS's Feb. 23 closing price on the ASX.
Scientists at Helmholtz Zentrum München have developed a new package called Scanpy that they hope will support major analytical efforts, such as the Human Cell Atlas.
The company plans to launch a single-cell CNV assay, a single cell ATAC-seq assay, and a single-cell feature barcoding assay later this year.
Paris-based Scipio will use the seed funding to further develop and commercialize its first prototype kit for single-cell transcriptomics.
Fluidigm said that Q3 mass cytometry product revenue more than doubled to $10.3 million from $5.1 million in the year-ago period.
Such an atlas could enable investigators to understand how genetic variants impact disease risk, define drug toxicities, improve therapies, and advance regenerative medicine.
In Science this week: ancient Neanderthal and human genomes, and more.
The UK-based company plans to use the funds to develop an automated, benchtop device for the creation of high-value, genome-edited cell lines.
The South San Francisco, California-based single-cell biology firm brought in $25.5 million compared to $29.0 million in the first quarter of 2016.
A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.
Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.
In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.
A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.